Clinical trial · Observational
Hepatocellular Carcinoma Identification Using Delta-HLD
Proof-of-Concept Case-Control Study for Hepatocellular Carcinoma Identification Using Delta-HLD Technology (HIDE)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
HIDE (Hepatocellular Carcinoma Identification via Delta-HLD) is a proof-of-concept case-control study designed to evaluate the performance of delta-HLD, Epiliquid's proprietary liquid biopsy technology, in detecting hepatocellular carcinoma (HCC). The study includes both plasma and tissue samples to assess biomarker concordance and evaluate diagnostic sensitivity and specificity using tumor-specific methylation markers detected by PCR.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepato Cellular Carcinoma (HCC) | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- HCC-cases
- description
- Patients with histologically confirmed hepatocellular carcinoma
- label
- Controls
- description
- Patients with liver cirrhosis without evidence of HCC
Primary outcomes (1)
- measure
- Sensitivity and Specificity of delta-HLD Technology
- timeFrame
- Within 3 months
- description
- Diagnostic performance of delta-HLD-detected methylation biomarkers in plasma and tissue, using clinical diagnosis of HCC (confirmed by histopathology) as the reference standard.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed HCC (cases) or clinically confirmed liver cirrhosis without HCC (controls) * Willing and able to provide informed consent * Available paired plasma and liver tissue sample Exclusion Criteria: * Other active cancers * Prior liver transplantation * Known hereditary cancer syndromes * Recent chemotherapy or antiviral treatment (\<3 months)
References
Publications (0)
Data not yet available